About Tasigna

Tasigna Safety and Tolerability

Tasigna is generally well tolerated and has demonstrated a low incidence of cross-intolerance with Glivec (imatinib mesylate). Tasigna also was associated with a low rate of Grade 3/4 nonhematologic AEs, including low AEs related to fluid retention.

Most nonhematologic AEs were mild to moderate in severity.

• The most common AEs in the chronic phase were rash, pruritus, nausea, headache, and fatigue.

Tasigna was associated with a low incidence of AEs related to fluid retention

• Low incidence (<1%) of Grade 3/4 pleural or pericardial effusions

Tasigna has a negligible incidence of cross-intolerance with Glivec

The most common hematologic AEs (Grade 3/4) were neutropenia and thrombocytopenia.

AEs are measured regardless of relation to Tasigna

• Prescribing Tasigna
• Tasigna Efficacy
• Tasigna Safety and Tolerability
• European Summary of Product Characteristics
• Tasigna Mechanism of Action
• How to Dose